DermaPrecise

DermaPrecise is an electronic multi-needle dermal injector to be used when consistent precision over depth, dose, and delivery matters. Owned by @RepliCel.

[AAD @AADskin]

Hair loss is one of the most common conditions that dermatologists. Learn more:
https://t.co/Kl9akLgROb #HairLossAwarenessMonth

[DermaPrecise @DermaPrecise]

The @RepliCel DermaPrecise Injector Shown to Produce Consistently High Cell Viability for Cell Therapy Injections. The Innovacell testing shows that DermaPrecise may greatly improve post-injection cell viability for injections into dermal or subcu tissue. https://t.co/DiVP2hYXR2

[DermaPrecise @DermaPrecise]

As @replicel said, we're excited to share our first dermal injector data showing consistent injection and distribution in donated skin tissue. When injection precision matters, we believe @DermaPrecise will be the only and best solution for intra-dermal + sub-cutaneous injections

[RepliCel Life Sciences Inc. @RepliCel]

Well that didn't go as planned! We've corrected the press release from earlier today as we used the wrong image - one intended for an upcoming release. Here's the corrected release and image. We're very excited to share the first @dermaprecise data!

https://t.co/LwgcCyPsSY

[RepliCel Life Sciences Inc. @RepliCel]

Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing. https://t.co/LnMT8dHGqp #dermtwitter #dermatology #dermalinjections #hairloss

[The Dermatologist @TheDermEditor]

The #eczema pipeline includes a number of biologic agents that target novel cytokines—IL-13 and IL-31. Watch April Armstrong, MD, MPH, discuss the evidence in this video: https://t.co/qD34SGTPQf
#dermtwitter #dermatology

[DermaPrecise @DermaPrecise]

Another great injectible approved. This one (by @LEOHealthySkin) for the treatment of the very painful atopic dermatitis. We are actively exploring the benefits of controlled, highly reproducible and precise, multi-needle dispersion for such treatment protocols.

[Dermatology Times @DermTimesNow]

Leo Pharma announced the FDA approval of Adbry for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older. Jonathan Silverberg, MD, PhD, MPH, clinical trial investigator gives his comments on this approval.
https://t.co/7BoNcrFY4t

[DermaPrecise @DermaPrecise]

@RepliCel's RCS-01 is just one example of many products in development for dermal injection + delivery which we believe will benefit from highly-controlled and precise micro-dose delivery using the DermaPrecise platform.
#dermalinjection #dermtwitter #dermatology #dermatologist

[RepliCel Life Sciences Inc. @RepliCel]

The extracellular matrix under skin loses ~1% of its collagen per year. By age 45, we face ~25% collagen loss causing a loss of skin support structure and elasticity. RCS-01 is in development to stimulate new collagen production using a patient's own cells. #naturalregeneration

[RepliCel Life Sciences Inc. @RepliCel]

The extracellular matrix under skin loses ~1% of its collagen per year. By age 45, we face ~25% collagen loss causing a loss of skin support structure and elasticity. RCS-01 is in development to stimulate new collagen production using a patient's own cells. #naturalregeneration

[Lt Col David Perez-Meza MD FISHRS ABHRS @drdaviperezmeza]

Very interesting article. There are so many variables with the MN and/or PRP techniques for hair loss. I do agree, a further research is needed. Thx for sharing.

[DermaPrecise @DermaPrecise]

@RepliCel has shipped DermaPrecise (tm) injector prototypes and consumables to an independent laboratory for clinical simulation testing in various types of donated human skin tissue.

https://t.co/lguwbVycld

[DermaPrecise @DermaPrecise]

@Hrzrsn1 @celltherapy @CCRM_ca We're the first to acknowledge this has taken long than expected, @Hrzns1. We continue to work to bring a next-gen solution to dermal injections. Our aim is to make a difference in the lives of patients and this who treat them. Thank you for your keeping up on task.

[The Dermatologist @TheDermEditor]

Prior to his session at Dermatology Week, Dr Hassan Galadari discussed updates in neuromodulators and injectable fillers including considerations on how to go about the procedures. Watch his discussion here: https://t.co/M6YJp8vjbD

#dermtwitter #cosmetic #dermatology

[AHMED ALZAMER @AHMEDALZAMER]

@najla_aldawsari FDA In Brief: FDA Warns Public and Health Care Professionals Not to Use Needle-free Devices for Injection of Dermal Fillers

https://t.co/DuC9zjmmMg

[DermaPrecise @DermaPrecise]

It's not a product launch (yet) but its a product and we are pleased to be launching the trademark to start building pre-market awareness for the #dermalinjector we've developed for use with injections where precision matters. https://t.co/fCZcDGqEmw @replicel @lifesciences_bc

[DermaPrecise @DermaPrecise]

We are very pleased to announce the name and trademark for the @RepliCel dermal injector.
DermaPrecise (tm) is an electronic multi-needle dermal injector to be used when consistent precision over depth, dose, and delivery matters.

https://t.co/dy4JKTnUql via @biospace